<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Shanghai Henlius Biotech, Inc. Class H — News on 6ix</title>
    <link>https://6ix.com/company/shanghai-henlius-biotech-inc</link>
    <description>Latest news and press releases for Shanghai Henlius Biotech, Inc. Class H on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Apr 2026 14:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/shanghai-henlius-biotech-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68368aeb78dffbe2df16c49c.webp</url>
      <title>Shanghai Henlius Biotech, Inc. Class H</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc</link>
    </image>
    <item>
      <title>European Commission (EC) Approves Henlius and Organon&apos;s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/european-commission-ec-approves-henlius-and-organons-poherdyr-pertuzumab-the-first-approved-biosimilar-to-perjeta-pertuzumab-in-europe-2</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/european-commission-ec-approves-henlius-and-organons-poherdyr-pertuzumab-the-first-approved-biosimilar-to-perjeta-pertuzumab-in-europe-2</guid>
      <pubDate>Wed, 29 Apr 2026 14:00:00 GMT</pubDate>
      <description>Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1</description>
    </item>
    <item>
      <title>Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/eisai-and-henlius-enter-into-exclusive-commercial-license-agreement-for-anti-pd-1-antibody-serplulimab-in-japan</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/eisai-and-henlius-enter-into-exclusive-commercial-license-agreement-for-anti-pd-1-antibody-serplulimab-in-japan</guid>
      <pubDate>Thu, 05 Feb 2026 11:44:00 GMT</pubDate>
      <description>Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, &quot;Henlius&quot;) announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) in Japan.</description>
    </item>
    <item>
      <title>Henlius Showcases &quot;Globalisation 2.0&quot; Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-showcases-globalisation-20-strategy-and-mid-to-long-term-innovation-blueprint-at-jpm-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-showcases-globalisation-20-strategy-and-mid-to-long-term-innovation-blueprint-at-jpm-2026</guid>
      <pubDate>Fri, 16 Jan 2026 13:00:00 GMT</pubDate>
      <description>The 44th J.P.Morgan Healthcare Conference (JPMHC) was successfully held in San Francisco, the United States, from January 12 to 15. As one of the most influential annual events in the global healthcare sector, JPM serves as a key platform for the capital markets and industry leaders to observe emerging trends in pharmaceutical innovation and industry development. The conference attracted more than 8000 global industry leaders, innovators, entrepreneurs, and investors. On January 15 (PST), Dr. Ja</description>
    </item>
    <item>
      <title>Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-ceo-dr-jason-zhu-to-deliver-a-keynote-presentation-at-jpm-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-ceo-dr-jason-zhu-to-deliver-a-keynote-presentation-at-jpm-2026</guid>
      <pubDate>Tue, 23 Dec 2025 13:53:00 GMT</pubDate>
      <description>The 44th J.P. Morgan Healthcare Conference will take place from January 12 to 15, 2026, in San Francisco, USA. Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius (2696.HK), has been invited to attend and will deliver a keynote presentation on January 15 (PST).</description>
    </item>
    <item>
      <title>Henlius&apos; Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-serplulimab-anti-pd-1-mab-granted-breakthrough-therapy-designation-by-china-nmpa-for-neo-adjuvant-treatment-for-gastric-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-serplulimab-anti-pd-1-mab-granted-breakthrough-therapy-designation-by-china-nmpa-for-neo-adjuvant-treatment-for-gastric-cancer</guid>
      <pubDate>Thu, 20 Nov 2025 10:52:00 GMT</pubDate>
      <description>Shanghai Henlius Biotech, Inc. (2696.HK) announced that its self-developed innovative anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab, Hetronifly® in Europe), in combination with chemotherapy for neo-/adjuvant treatment for gastric cancer, has been officially granted the Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This marks the first gastric cancer perioperative drug to receive the CDE&apos;s BTD. Previ</description>
    </item>
    <item>
      <title>Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-and-organon-announce-us-fda-approval-of-poherdyr-pertuzumab-dpzb-the-first-perjeta-pertuzumab-biosimilar-in-the-us</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-and-organon-announce-us-fda-approval-of-poherdyr-pertuzumab-dpzb-the-first-perjeta-pertuzumab-biosimilar-in-the-us</guid>
      <pubDate>Mon, 17 Nov 2025 14:06:00 GMT</pubDate>
      <description>Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.[1] POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality</description>
    </item>
    <item>
      <title>Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/forlong-biotechology-announces-collaboration-agreement-with-henlius-to-develop-innovative-cancer-immunotherapy-with-an-engineered-cytokine</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/forlong-biotechology-announces-collaboration-agreement-with-henlius-to-develop-innovative-cancer-immunotherapy-with-an-engineered-cytokine</guid>
      <pubDate>Wed, 22 Oct 2025 13:00:00 GMT</pubDate>
      <description>SHANGHAI &amp; SUZHOU, China, October 22, 2025--Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that it has entered into a collaboration agreement with Shanghai Henlius Biotech, Inc., (2696.HK) (&quot;Henlius&quot;) to develop innovative cancer immunotherapy with an engineered cytokine.</description>
    </item>
    <item>
      <title>Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/phase-3-clinical-trial-of-hansizhuang-plus-chemotherapy-meets-primary-endpoint-in-neoadjuvantadjuvant-gastric-cancer-greenlighting-early-nda-submission</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/phase-3-clinical-trial-of-hansizhuang-plus-chemotherapy-meets-primary-endpoint-in-neoadjuvantadjuvant-gastric-cancer-greenlighting-early-nda-submission</guid>
      <pubDate>Thu, 09 Oct 2025 12:50:00 GMT</pubDate>
      <description>Shanghai Henlius Biotech, Inc. (2696.HK) announced that its self-developed innovative anti-PD-1 monoclonal antibody, HANSIZHUANG (serplulimab, Hetronifly® in Europe), in combination with chemotherapy for the neoadjuvant/adjuvant monotherapy treatment of gastric cancer, has met the primary endpoint of Event-Free Survival (EFS) in an interim analysis of its phase 3 clinical study (ASTRUM-006). This outcome represents a breakthrough, making it the world-first regimen to replace adjuvant chemotherap</description>
    </item>
    <item>
      <title>European Commission (EC) Approves Henlius and Organon&apos;s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/european-commission-ec-approves-henlius-and-organons-bildyosr-denosumab-and-bilprevdar-denosumab-biosimilars-to-prolia-denosumab-and-xgeva-denosumab-respectively</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/european-commission-ec-approves-henlius-and-organons-bildyosr-denosumab-and-bilprevdar-denosumab-biosimilars-to-prolia-denosumab-and-xgeva-denosumab-respectively</guid>
      <pubDate>Fri, 19 Sep 2025 11:58:00 GMT</pubDate>
      <description>Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.[1],[2]</description>
    </item>
    <item>
      <title>FUTUONING Sets Sail Commercially with First Prescriptions Across China</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/futuoning-sets-sail-commercially-with-first-prescriptions-across-china</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/futuoning-sets-sail-commercially-with-first-prescriptions-across-china</guid>
      <pubDate>Fri, 05 Sep 2025 10:12:00 GMT</pubDate>
      <description>These days, the first prescriptions of FUTUONING (fovinaciclib citrate capsules) were issued by more than ten hospitals across China, including Fudan University Shanghai Cancer Center, Cancer Hospital of the Chinese Academy of Medical Sciences, The First Affiliated Hospital Zhejiang University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Shandong Cancer Hospital, Shanghai Tenth People&apos;s Hospital, Nanjing Drum Tower Hospital and The Affiliated Hospital of Qingdao</description>
    </item>
    <item>
      <title>US Food and Drug Administration (FDA) Approves Henlius and Organon&apos;s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/us-food-and-drug-administration-fda-approves-henlius-and-organons-bildyosr-denosumab-nxxp-and-bilprevdar-denosumab-nxxp-biosimilars-to-prolia-denosumab-and-xgeva-denosumab-respectively</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/us-food-and-drug-administration-fda-approves-henlius-and-organons-bildyosr-denosumab-nxxp-and-bilprevdar-denosumab-nxxp-biosimilars-to-prolia-denosumab-and-xgeva-denosumab-respectively</guid>
      <pubDate>Tue, 02 Sep 2025 13:10:00 GMT</pubDate>
      <description>Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.1,2</description>
    </item>
    <item>
      <title>Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-keeps-steady-growth-in-h1-2025-overseas-product-profits-soar-200percent-innovation-fuels-global-reach</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-keeps-steady-growth-in-h1-2025-overseas-product-profits-soar-200percent-innovation-fuels-global-reach</guid>
      <pubDate>Mon, 25 Aug 2025 13:18:00 GMT</pubDate>
      <description>Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius&apos; revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390.1 million. Operating cash flow reached RMB770.9 million, with an increase of 206.8% YoY, maintaining a steady positive inflow. Overseas products profits surged over 200%. Cash inflows from BD agreements exceeded RMB 1 billion, surging 280% Yo</description>
    </item>
    <item>
      <title>HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/hanchorbio-and-henlius-sign-major-licensing-deal-for-hcb101-to-expand-global-immuno-oncology-reach</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/hanchorbio-and-henlius-sign-major-licensing-deal-for-hcb101-to-expand-global-immuno-oncology-reach</guid>
      <pubDate>Tue, 01 Jul 2025 05:40:00 GMT</pubDate>
      <description>HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement with Shanghai Henlius Biotech, Inc. (hereafter &quot;Henlius&quot;). The deal grants Henlius exclusive development and commercialization rights to HCB101 across Greater China (including Mainland China, Hong Kong, and Macau), key Southeast Asian countries, as well as all countries in the Middle Ea</description>
    </item>
    <item>
      <title>Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-enters-into-license-agreement-with-sandoz-for-proposed-ipilimumab-biosimilar</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-enters-into-license-agreement-with-sandoz-for-proposed-ipilimumab-biosimilar</guid>
      <pubDate>Tue, 29 Apr 2025 15:38:00 GMT</pubDate>
      <description>On April 29, 2025, Shanghai Henlius Biotech, Inc. (2696.HK) announced a licensing agreement with Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, granting exclusive commercialization rights for its self-developed ipilimumab biosimilar HLX13 in the United States, 42 European countries and regions, Japan, Canada, and Australia.</description>
    </item>
    <item>
      <title>Henlius 2025 Global R&amp;D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-2025-global-randd-day-harnessing-the-power-of-innovation-to-propel-global-strategy-to-new-heights</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-2025-global-randd-day-harnessing-the-power-of-innovation-to-propel-global-strategy-to-new-heights</guid>
      <pubDate>Thu, 17 Apr 2025 08:07:00 GMT</pubDate>
      <description>Henlius (2696.HK) held its 2025 Global R&amp;D Day themed &quot;Collaborate to Create,&quot; gathering senior executives, experts, and industry leaders to discuss R&amp;D advances, strategic planning, and cutting-edge therapies. The event attracted hundreds from academia, industry, and investment sectors.</description>
    </item>
    <item>
      <title>Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/putting-patients-first-co-creating-a-bright-future-for-human-health-henlius-releases-2024-esg-report</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/putting-patients-first-co-creating-a-bright-future-for-human-health-henlius-releases-2024-esg-report</guid>
      <pubDate>Wed, 16 Apr 2025 15:22:00 GMT</pubDate>
      <description>On April 15, 2025, Henlius (2696.HK) released the &quot;2024 Environmental, Social, and Governance (ESG) Report&quot; (hereinafter referred to as the &quot;ESG Report&quot; or &quot;Report&quot;). This marks the sixth consecutive year that the company has submitted an ESG-related report to global stakeholders, comprehensively showcasing Henlius&apos; remarkable achievements and steadfast commitment across 5 key ESG pillars: Product, Talent, Environment, Society, and Corporate Governance.</description>
    </item>
    <item>
      <title>Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-2024-annual-results-steady-revenue-growth-with-a-net-profit-of-rmb8205-million-up-by-503percent-yoy</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-2024-annual-results-steady-revenue-growth-with-a-net-profit-of-rmb8205-million-up-by-503percent-yoy</guid>
      <pubDate>Mon, 24 Mar 2025 15:09:00 GMT</pubDate>
      <description>Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius&apos; total revenue reached approximately RMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reached RMB820.5 million, a 50.3% YoY growth, with a net profit margin of 14.3%, up by 41.6% YoY. This marks Henlius&apos; second consecutive year of full-year profitability following its first profitable year in 2023. The increasing commercial sales of core products have been a key driver of profitabilit</description>
    </item>
    <item>
      <title>Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer</title>
      <link>https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-receives-orphan-drug-designation-for-innovative-anti-her2-mab-hlx22-in-the-us-for-gastric-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-henlius-biotech-inc/news/henlius-receives-orphan-drug-designation-for-innovative-anti-her2-mab-hlx22-in-the-us-for-gastric-cancer</guid>
      <pubDate>Wed, 19 Mar 2025 15:17:00 GMT</pubDate>
      <description>Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company&apos;s innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer.</description>
    </item>
  </channel>
</rss>